Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17758565 | 0.91 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2TSHR | |
| SCHEMBL17758515 | 0.82 | — | — | |
| SCHEMBL3079040 | 0.77 | CYP1A2 (0.48) | MEN1CYP1A2KMT2ASMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL11403921 | 0.74 | MEN1 (0.46) | MEN1CYP1A2KMT2ASMN1; SMN2TSHR | |
| SCHEMBL17407236 | 0.73 | — | — | |
| SCHEMBL17758572 | 0.73 | KDM4E (0.37) | MEN1CYP1A2KMT2ASMN1; SMN2TSHR | |
| SCHEMBL13526678 | 0.73 | EPHX1 (0.47) | MEN1CYP1A2KMT2ASMN1; SMN2TSHR | |
| SCHEMBL11434568 | 0.73 | POLB (0.36) | KMT2A | |
| SCHEMBL11222356 | 0.72 | MAPK1 (0.41) | SMN1; SMN2TSHRHIF1AALOX15 | |
| SCHEMBL395191 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220412963-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11353461-B2 | Methods of enhancing MS detection of tagged glycans | WATERS TECHNOLOGIES CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | WATERS TECHNOLOGIES CORPORATION (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190219587-A1 | METHODS OF ENHANCING MS DETECTION OF TAGGED GLYCANS | WATERS TECHNOLOGIES CORPORATION | 2019-07-18 | — | — | US | disclosed |
| US-20160139136-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | FUT5, FUT6, OGT | MEN1 3289/4885CYP1A2 2545/4885KMT2A 2258/4885 |
| US-20220412963-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | FUT5, FUT6, OGT | MEN1 3289/4885CYP1A2 2545/4885KMT2A 2258/4885 |
| US-20160139136-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | FUT5, FUT6, CSGALNACT1 | MEN1 2746/4885CYP1A2 4637/4885KMT2A 3081/4885 |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | FUT5, FUT6, OGT | MEN1 3289/4885CYP1A2 2545/4885KMT2A 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.